期刊文献+

体外转录信使RNA免疫疗法的研究进展 被引量:8

下载PDF
导出
摘要 体外转录信使RNA(IVT mRNA)是在体外条件下以DNA为模板转录得到的一种mRNA,这种mRNA可以指导特定蛋白质的合成,阻止或改变某种特定的疾病。因此,IVT mRNA可以作为一种传递遗传信息的潜在新药。与其他核酸药物相比,基于IVT mRNA的药物具有很多优势。随着mRNA技术发展,基于IVT mRNA的恶性肿瘤免疫疗法和治疗传染性疾病疫苗的研制等已步入临床应用阶段。本文系统地介绍了IVT mRNA的结构、合成方式、投递途径和免疫机制,着重分析了IVT mRNA免疫疗法在不同疾病临床治疗中的应用现状,如恶性肿瘤、传染性疾病和过敏反应等,并探讨了将其开发为新药所遇到的关键性机遇与挑战。
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2016年第1期129-132,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金(81070951 81222015) 第四军医大学博士学位资助课题(2013D01)
  • 相关文献

参考文献36

  • 1Vik-Mo E O, Nyakas M, Mikkelsen B V, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma[ J]. Cancer Immunol Immunother, 2013, 62(9) : 1499 - 1509.
  • 2Allard S D, De Keersmaecker B, de Goede A L, et al. A phase I/Ila immunotherapy trial of HIV-l-infected patients with Tat, Rev and Nef expressing dendritic cellsfoUowed by treatment interruption[J]. Clin Immunol, 2012, 142(3) : 252 -268.
  • 3Roesle E, Weiss R, WeinbeeT E E, et al. Imratmize and disappear- safety-op'tnnized mRNA vaccination with a panel of 29 allergens [J/OL]. J Allergy Clin Immunol, 2009, 124(5) : 1070 - 1077.doi: 10. 1016/j. jaci. 2009.06. 036. Epub 2009 Aug 8. _ _.
  • 4Gros F, Gilbert W, Hiatt H H, et al. Molecular and biological characterization of messenger RNA [ J ]. Cold Spring Harb Syrup Quant Biol, 1961, 26:111-132.
  • 5Wolff J A, Malone R W, Williams P, et al. Direct gene transfer into mouse muscle in vivo [ J ]. Science, 1990, 247 ( 4949 Pt 1 ) : 1465 - 1468.
  • 6Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA [ J ]. Eur J Immunol, 1993, 23(7): 1719-1722.
  • 7Grudzien-Nogalska E, Kowalska J, Su W, et al. Synthetic mRNAs with superior translation and stability properties [ J ]. Methods Mol Bid, 2013, 969:55 -72.
  • 8Wilgenhof S, Van Nuffel A M, Benteyn D, et al. A phase I B study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients [ J ]. Ann Oncol, 2013, 24(10) : 2686 -2693.
  • 9Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy [ J ]. Cancer Res, 2012, 72(7): 1661 -1671.
  • 10Van Nuffel A M, Benteyn D, Wflgenhof S, et al. Intravenous and intradennal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-Mlc melanoma patient [ J ]. Cancer Immunol Inmaunother, 2012, 61 ( 7 ) : 1033 - 1043.

同被引文献13

引证文献8

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部